Trial
NCT00818649
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.
Condition
Leukemia
Intervention
bortezomib
Why stopped
Met protocol stop rule \[i.e., extreme toxicity\]
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28